Kezar Life Sciences, Inc. (NASDAQ:KZR) Forecasted to Post FY2024 Earnings of ($0.97) Per Share

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Investment analysts at HC Wainwright increased their FY2024 earnings per share estimates for Kezar Life Sciences in a report issued on Wednesday, August 14th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.97) per share for the year, up from their previous estimate of ($0.98). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.82) EPS.

Kezar Life Sciences Price Performance

NASDAQ:KZR traded up $0.00 during mid-day trading on Friday, reaching $0.63. 37,987 shares of the company were exchanged, compared to its average volume of 653,583. The company has a quick ratio of 11.49, a current ratio of 11.48 and a debt-to-equity ratio of 0.05. The stock has a market cap of $45.66 million, a PE ratio of -0.46 and a beta of 0.28. Kezar Life Sciences has a 12 month low of $0.54 and a 12 month high of $1.69. The company has a fifty day moving average of $0.63 and a 200 day moving average of $0.78.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its position in Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after buying an additional 71,543 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Kezar Life Sciences by 42.5% in the first quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock valued at $1,613,000 after acquiring an additional 534,203 shares during the last quarter. Panagora Asset Management Inc. bought a new position in Kezar Life Sciences in the fourth quarter valued at about $80,000. SG Americas Securities LLC increased its position in Kezar Life Sciences by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 43,950 shares of the company’s stock worth $42,000 after purchasing an additional 11,109 shares during the period. Finally, Mackenzie Financial Corp bought a new stake in Kezar Life Sciences during the 2nd quarter worth about $35,000. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.